

NanoFar is an Erasmus Mundus Joint Doctorate programme selected in 2011 by EACEA.

This European program is coordinated by the University of Angers (France), and involves the Universities of Nantes (France), Liège and Louvain (Belgium), Nottingham (United Kingdom) and Santiago de Compostela (Spain).

NanoFar allows student to complete a three-year PhD thesis, co-supervised by partners in two different countries and including a **one-year mobility period** in a partner country.

Leading European academic teams working together on the **integrative approaches to nanomedicine**, it aims to train the best students in the field of Nanomedicine at the doctoral level.

9 Erasmus Mundus Doctorate fellowships (covering tuition fees, participation costs, travel expenses, some household expenses contribution and a monthly allowance) **will be offered in 2013 by the EMJD NanoFar consortium to students from all over the world.**

Additionally, fellowships locally funded will be available.

The Doctorate course has 120 ECTS credits dedicated to laboratory based research, and 60 ECTS credits for training activities, including 3 mandatory summer schools.



What is Erasmus Mundus?

NanoFar has been selected by the European Commission to take part of the **Erasmus Mundus Program**, which is an European Commission initiative supporting university cooperation at the master's and doctoral levels and aims to provide top-quality European education to attract the best students worldwide.

This program aims to enhance the quality of European higher education and to promote dialogue and understanding between people and cultures through cooperation with Third-Countries.

NanoFar details:

| | |
|---------------------|--|
| Website | www.erasmusmundus-nanofar.eu |
| Contact | contact@erasmusmundus-nanofar.eu |
| Application process | Open until January 31 th , 2013 |
| PhD project offers | www.erasmusmundus-nanofar.eu/phd-project-offers |
| Applications | www.erasmusmundus-nanofar.eu/how-to-apply |

NanoFar

European Doctorate
in nanomedicine and
pharmaceutical innovation